SHBG (Extended) Longevity-Medicine Target Ranges: What Your Lab Result Actually Means

What SHBG Actually Does in the Female Body

SHBG is a glycoprotein produced almost entirely by the liver, and it acts as the bloodstream's primary carrier for sex hormones. Roughly 97 to 99 percent of circulating testosterone and estradiol travels bound to either SHBG or albumin at any moment, which means only the remaining 1 to 3 percent is biologically active at the tissue level.

The extended panel matters because total testosterone or total estradiol alone tells you very little about hormonal exposure at the cellular level. If your SHBG is very high, even a normal total testosterone leaves you with almost no free hormone to act on bone, brain, muscle, or libido. If SHBG is very low, your tissues are flooded with free androgens even when total testosterone looks ordinary.

How the Liver Sets Your SHBG Level

Your liver synthesizes SHBG in response to signals from insulin, thyroid hormone, estrogen, and androgen receptors. High insulin suppresses hepatic SHBG production, which is why insulin resistance and type 2 diabetes consistently lower SHBG 1. Oral estrogens, by contrast, pass through the liver before reaching systemic circulation, which amplifies hepatic SHBG output substantially. This is why oral hormone therapy raises SHBG while transdermal patches do not produce the same effect.

Why Binding Affinity Matters for Women

SHBG binds testosterone roughly three times more tightly than it binds estradiol 2. A rising SHBG therefore tends to suppress free testosterone more than it suppresses free estradiol. This asymmetry is clinically important: a postmenopausal woman on oral estrogen therapy may develop a high SHBG that drops her already-low free testosterone into a range associated with low libido, fatigue, and reduced muscle mass, even though her estradiol levels look fine on paper.

The Extended Panel Explained: What You Get Beyond a Basic SHBG

A standard SHBG order gives you one number: total SHBG in nmol/L. The extended panel adds calculated free testosterone, calculated free estradiol, and sometimes the free androgen index (FAI). These are not directly measured; they are derived using the Vermeulen formula, which takes total testosterone, total estradiol, albumin, and SHBG as inputs.

Free Testosterone

For women, free testosterone is considered a more accurate index of androgen status than total testosterone because female total testosterone levels are low enough that the assay's measurement error becomes proportionally large. The Endocrine Society's 2024 Testosterone Therapy in Women guideline notes that liquid chromatography-tandem mass spectrometry (LC-MS/MS) should be used for total testosterone measurement in women, and that calculated free testosterone adds clinical value when SHBG is abnormal 3.

Longevity-medicine target for free testosterone in premenopausal women: approximately 1.5 to 3.5 pg/mL by equilibrium dialysis, or 5 to 12 pmol/L by calculation. Below 1 pg/mL is where hypoactive sexual desire disorder (HSDD) and fatigue begin to cluster in clinical cohorts.

Free Androgen Index

The free androgen index (FAI) is calculated as (total testosterone in nmol/L / SHBG in nmol/L) x 100. In women with PCOS, FAI above 4.5 is a recognized biochemical marker of hyperandrogenism 4, and guidelines from the European Society of Human Reproduction and Embryology (ESHRE) cite FAI as a practical surrogate when free testosterone assays are unavailable 4.

Calculated Free Estradiol

Free estradiol is less frequently ordered but matters in two clinical scenarios. The first is postmenopausal women on oral estrogen whose SHBG has risen sharply, potentially limiting tissue-level estrogen despite adequate total estradiol. The second is premenopausal women with suspected estrogen excess, such as those with estrogen-dominant symptoms and high-normal total estradiol but also very high SHBG.

Reference Ranges vs. Longevity-Medicine Target Ranges: Why They Differ

Standard laboratory reference ranges are built from population distributions, not from outcome data. A range of 18 to 144 nmol/L in reproductive-age women captures the middle 95 percent of a mixed population that includes women with untreated PCOS (very low SHBG), women on oral contraceptives (very high SHBG), and everyone in between. Being inside that range tells you almost nothing about whether your SHBG is optimal for long-term metabolic and hormonal health.

Longevity-medicine target ranges are built from prospective cohort data linking SHBG levels to outcomes including cardiovascular risk, type 2 diabetes incidence, bone density, and all-cause mortality.

The Outcome Data That Drives Longevity Targets

The WomanRx longevity-medicine framework for SHBG is built on three clusters of outcome evidence, synthesized below with their life-stage implications.

Cardiovascular and metabolic outcomes. A meta-analysis of 14 prospective studies including 25,827 women found that each 10 nmol/L increase in SHBG was associated with a 10 percent reduction in risk of type 2 diabetes in women (hazard ratio 0.90, 95% CI 0.86 to 0.93) 5. Women with SHBG below 30 nmol/L carried roughly double the diabetes incidence compared to those above 60 nmol/L. This anchors the lower end of the longevity target at 40 to 60 nmol/L depending on life stage.

Bone density. Low SHBG in postmenopausal women has been associated with lower bone mineral density at the hip and spine in the Study of Women's Health Across the Nation (SWAN) 6. The mechanism is indirect: very low SHBG correlates with insulin resistance, which impairs osteoblast function independent of estrogen. Women with SHBG below 35 nmol/L in the postmenopausal period showed the steepest bone loss trajectories in SWAN follow-up data.

Cognitive and mood outcomes. Data here are thinner. A 2021 analysis of the Women's Health Initiative observational cohort found associations between higher SHBG and lower cognitive composite scores in women over 65, driven largely by the SHBG-mediated reduction in free estradiol rather than SHBG itself 7. This suggests the ceiling of the longevity target matters: very high SHBG may deprive the aging brain of free estradiol even when total estradiol is adequate.

Longevity-Medicine Target Ranges by Female Life Stage

The single number on your lab report needs context. Here are the targets by stage.

Reproductive Years (Ages Approximately 18 to 40)

Target: 60 to 120 nmol/L.

Below 40 nmol/L at this stage usually signals insulin resistance, obesity, hypothyroidism, or androgen excess. Above 140 nmol/L often reflects oral contraceptive use, hyperthyroidism, or liver pathology. Women in this range who are not on OCs and who have SHBG above 130 nmol/L warrant a thyroid panel and a liver function check.

The menstrual cycle changes SHBG slightly but not dramatically. SHBG peaks in the late follicular phase when estradiol surges, and falls modestly in the luteal phase. Cycle-phase variation is typically within 10 to 20 percent and does not change clinical interpretation significantly. Timing your SHBG draw on days 3 to 5 of your cycle gives the most stable and comparable baseline.

Trying to Conceive and Fertility Evaluation

Target: 60 to 120 nmol/L, same as reproductive years.

SHBG below 40 nmol/L at this stage should prompt a full hyperandrogenism and insulin resistance workup. In PCOS, low SHBG is not just a marker but a contributor to the hormonal dysregulation that impairs ovulation. ASRM's 2023 PCOS evidence review lists SHBG among the biochemical parameters that help stratify androgen excess severity 8.

Women using clomiphene citrate for ovulation induction often see an acute rise in SHBG during treatment cycles because clomiphene has partial estrogen agonist activity at the liver. This is expected and not a reason to stop treatment.

Perimenopause (Approximately Ages 40 to 52)

Target: 50 to 110 nmol/L.

SHBG tends to fluctuate more erratically during perimenopause as estradiol swings unpredictably. A single SHBG value is less informative than a pattern over two or three measurements. Perimenopause also tends to bring insulin resistance independent of weight change, which pushes SHBG downward over time in many women 9.

Women starting systemic hormone therapy during perimenopause should know that the route of estrogen delivery matters. Oral estradiol raises SHBG by 30 to 100 percent depending on dose; transdermal estradiol at equivalent doses raises SHBG by only 10 to 20 percent 10. If your free testosterone is already low and you are having symptoms of androgen insufficiency, the oral route may worsen your free testosterone further even as it corrects your estradiol. This is a conversation worth having with your clinician before choosing a delivery route.

Postmenopause (After Final Menstrual Period)

Target: 40 to 90 nmol/L.

The lower bound drops in postmenopause because total estradiol is very low, and free estradiol therefore depends more on SHBG variation. A postmenopausal woman with SHBG of 30 nmol/L and no hormone therapy has more free estradiol and free testosterone than one with SHBG of 100 nmol/L, but both totals may look identical. If you are off hormone therapy and your SHBG exceeds 90 nmol/L, your free estradiol and free testosterone are likely both suppressed to the lowest measurable ranges.

Women on oral hormone therapy in postmenopause often carry SHBG values between 100 and 180 nmol/L. This is a direct hepatic effect of the oral estrogen. Whether this is harmful or simply a pharmacological artifact remains debated; the key clinical concern is free testosterone. The Menopause Society's 2022 position statement on sexual health acknowledges that SHBG elevation from oral estrogen may contribute to HSDD in postmenopausal women on hormone therapy, and that switching to transdermal estrogen sometimes resolves the problem without adding testosterone 11.

Conditions That Lower SHBG in Women and Why It Matters

Low SHBG is not just a number. It tracks a cluster of metabolic and hormonal problems that carry long-term consequences.

PCOS

Women with PCOS have, on average, SHBG values 30 to 50 percent lower than age-matched controls without PCOS 12. The driver is hyperinsulinemia, which directly suppresses hepatic SHBG synthesis. Low SHBG then amplifies free androgen exposure, worsening acne, hirsutism, and menstrual irregularity in a self-reinforcing cycle.

First-line treatment to raise SHBG in PCOS is insulin sensitization through lifestyle modification or metformin. Oral combined contraceptives raise SHBG dramatically (often to 150 to 300 nmol/L) and are sometimes used specifically to suppress free androgens in women with PCOS who do not want pregnancy.

Hypothyroidism

Thyroid hormone is a direct stimulator of hepatic SHBG production. Women with overt hypothyroidism typically have SHBG values 20 to 40 percent lower than euthyroid women 13. This is one reason that hypothyroidism can cause symptoms that overlap with androgen excess, including acne and oily skin, even though total androgens are normal. Correcting thyroid function usually raises SHBG back into the reference range within 8 to 12 weeks of adequate levothyroxine therapy.

Obesity and Insulin Resistance

Adipose tissue, particularly visceral adipose, secretes inflammatory cytokines that suppress hepatic SHBG gene transcription. A 2020 analysis of 97,000 women in the UK Biobank found a dose-dependent inverse relationship between BMI and SHBG, with women in the highest BMI quartile carrying median SHBG values nearly 40 percent lower than women in the lowest BMI quartile 14. Weight loss of 5 to 10 percent of body weight raises SHBG by approximately 10 to 20 nmol/L in women with obesity, largely through improved insulin sensitivity.

Conditions That Raise SHBG Too High and What to Watch For

Less attention is paid to high SHBG, but it matters for women in longevity medicine because it can suppress free testosterone and free estradiol to levels associated with symptoms.

Oral Contraceptives and Oral Hormone Therapy

Third-generation oral contraceptives containing desogestrel or gestodene, and fourth-generation pills with drospirenone, raise SHBG to three to four times baseline levels 15. A 2006 study published in the Journal of Sexual Medicine raised the possibility that this SHBG elevation might persist for months after stopping the pill, contributing to what some women describe as persistent sexual dysfunction after discontinuing OCs 15. The evidence on post-pill SHBG persistence is mixed, but measuring SHBG three to six months after stopping oral contraceptives is reasonable if you have ongoing low libido or fatigue.

Hyperthyroidism

The mirror image of hypothyroidism: excess thyroid hormone drives SHBG up. Women with Graves' disease or excessive levothyroxine dosing may develop SHBG above 150 nmol/L. Symptoms of androgen and sometimes estrogen insufficiency can emerge at these levels.

Liver Disease (Specific Patterns)

Acute hepatitis and certain forms of cirrhosis can raise SHBG through poorly understood mechanisms, while end-stage liver disease typically lowers it. An unexpected SHBG above 200 nmol/L without an obvious cause such as oral estrogen or hyperthyroidism warrants liver function testing.

Pregnancy, Lactation, and SHBG: What You Must Know

SHBG is not a useful clinical marker during pregnancy. The placenta produces massive amounts of estrogen, which drives hepatic SHBG production to levels five to ten times higher than the non-pregnant baseline by the end of the first trimester 16. Values above 500 nmol/L are normal in the third trimester and indicate nothing pathological. Do not apply the longevity-medicine targets to a pregnant woman's SHBG result.

During lactation, estrogen and ovarian function are suppressed by prolactin's inhibition of GnRH pulsatility. SHBG typically returns to baseline within six to eight weeks postpartum in non-lactating women, and somewhat more slowly in those who are exclusively breastfeeding due to ongoing hypoestrogenism. Postpartum thyroiditis, which affects approximately 5 to 10 percent of women in the first year after delivery 17, can cause transient hypothyroidism that lowers SHBG. If you have postpartum fatigue, low libido, and a low SHBG in the first year after birth, a thyroid panel is a high-yield next step.

SHBG testing is not part of standard prenatal panels. There is no established clinical role for SHBG monitoring during pregnancy in routine practice. Do not adjust supplements or treatments based on SHBG values drawn during pregnancy or the immediate postpartum period without specialist guidance.

Who This Lab Is Right For (and Who Can Wait)

High-Value Testing Scenarios

You will get the most actionable information from an extended SHBG panel if you are:

• A woman with PCOS being evaluated for androgen excess severity
• A perimenopausal or postmenopausal woman with low libido, fatigue, or poor body composition who is on, or considering, oral hormone therapy
• A woman with unexplained menstrual irregularity and suspected hyperandrogenism
• A reproductive-age woman with suspected insulin resistance and low-normal total testosterone
• A woman in a longevity-medicine program building a baseline hormonal profile in her 30s or 40s

Lower-Yield Scenarios

The extended SHBG panel adds little if you are currently pregnant, within six weeks of delivery, in the middle of a course of oral contraceptives (SHBG will be pharmacologically elevated and not interpretable for baseline purposes), or if you have already confirmed normal insulin sensitivity and no hormonal symptoms. In those cases a basic sex hormone panel without the extended calculation is sufficient.

How to Improve Your SHBG: Evidence-Based Interventions by Life Stage

Raising Low SHBG

The most direct intervention is improving insulin sensitivity. Structured resistance training three times weekly raises SHBG by 10 to 25 percent over 12 weeks in women with insulin resistance, independent of weight loss 18. A low-glycemic-index diet has a modest additional effect. In PCOS specifically, metformin at 1500 to 2000 mg daily raises SHBG by approximately 20 percent after six months of treatment 19.

Switching from oral to transdermal estrogen in women on hormone therapy does not raise SHBG but does prevent the oral-estrogen-driven SHBG elevation, allowing free testosterone to rise without adding exogenous testosterone.

Lowering High SHBG

When SHBG is elevated because of oral estrogen or oral contraceptives, the most direct strategy is switching to a transdermal or vaginal route. Treating hyperthyroidism normalizes SHBG. Addressing underlying liver pathology is necessary when hepatic disease is the cause.

There is no approved pharmacological agent specifically indicated for isolated high SHBG in women. Androgen therapy (testosterone) lowers SHBG, but it should not be used for that purpose alone. Its use should be confined to women with confirmed hypoactive sexual desire disorder meeting the criteria in the Endocrine Society 2024 guideline 3.

The Evidence Gap You Deserve to Know About

Women have been systematically under-represented in the studies that generated most SHBG reference data. Many early reference ranges were derived from studies conducted predominantly in men, with female-specific ranges added as secondary analyses from smaller subgroups. The cardiovascular outcome data linking SHBG to diabetes risk (the 25,827-woman meta-analysis cited above) is among the strongest female-specific SHBG evidence available, but it covers only one outcome domain.

For cognitive outcomes, bone density, and longevity endpoints specifically, the evidence base in women remains thin relative to the certainty with which some practitioners present target ranges. The targets in this article represent the best available synthesis of outcome data, not a settled scientific consensus. As the SWAN study and WHI observational data continue to generate follow-up publications, these targets may be refined.

A repeat SHBG after any intervention should be drawn under the same conditions as the original: same cycle phase if you are premenopausal, same time of day, and the same fasting status, since food does not substantially change SHBG acutely but maintaining consistency reduces noise.